Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

the first-ever approval for a mesenchymal stromal cell (MSC) therapy in the US. The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...